Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Personalized Radiotherapeutic Approaches for Elderly Patients with Epidural Cord Compression from Gastric Cancer

DIRK RADES, STEVEN E. SCHILD, AMIRA BAJROVIC, STEFAN JANSSEN and TOBIAS BARTSCHT
In Vivo January 2016, 30 (1) 69-72;
DIRK RADES
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rades.dirk@gmx.net
STEVEN E. SCHILD
2Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AMIRA BAJROVIC
3Department of Radiation Oncology, University Medical Center Eppendorf, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEFAN JANSSEN
1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
4Medical Practice for Radiotherapy and Radiation Oncology, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOBIAS BARTSCHT
5Department of Hematology and Medical Oncology, University of Lübeck, Lübeck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: To facilitate personalization of radiotherapy (RT) for elderly patients with epidural cord compression (ECC) from gastric cancer. Patients and Methods: Several factors were analyzed for survival in 20 elderly patients including age, gender, time period from gastric cancer diagnosis to ECC, metastatic spread, additional osseous lesions, vertebral bodies afflicted by ECC, ambulatory function, dynamic of motor dysfunction, performance status and RT fractionation. Results: Four factors had a significant influence on survival: metastatic spread (p<0.001), ambulatory function (p=0.001), dynamics of motor dysfunction (p=0.002) and performance status (p=0.003). Points were assigned according to factors present for each patient. To avoid confounding variables, performance status was not incorporated into the scoring system. Based on 3-month survival rates, patients were divided into four groups according to the total score: 6, 12-13, 19 and 26 points. Three-month survival rates for these groups were 0%, 50%, 75% and 100%, respectively (p<0.001). Conclusion: This score is of great assistance when assigning the appropriate RT approach to an elderly patient with ECC from gastric cancer.

  • Gastric cancer
  • epidural cord compression
  • elderly patients
  • personalization of treatment

In adult patients with epidural cord compression (ECC), gastric cancer accounts for approximately 2% of all primaries (1). About 50% of these patients are elderly patients, meaning age 65 years or more according to the definition of the World Health Organization (2). Because elderly patients are different from younger and middle-aged patients, they deserve specific consideration in the field of oncology (3, 4). Elderly patients generally have a lower metabolic rate, a different distribution of fat tissue, a less competent immune system and are more likely to suffer from chronic diseases. Anticancer treatment must take into account a patient's age and the fact that many elderly patients are not capable of tolerating aggressive therapies. In general, elderly patients require personalized treatment approaches to a greater extent than younger ones. Such approaches can be much more easily realized with the application of prognostic indices. Due to the differences between elderly and younger patients with cancer, such indices should be separately designed for each age group. Furthermore, separate indices should be available for single tumor entities that differ considerably regarding outcomes and prognoses. In order to achieve optimal personalized care of elderly patients with ECC from gastric cancer, the major goal of this study was the development of a prognostic index customized specifically for the specific patient group.

Patients and Methods

Twenty patients conventionally irradiated for ECC from gastric cancer were included. All patients were 65 years of age or older and, according to the World Health Organization defined as “elderly”. The primary end-point was survival. Several factors were analyzed for this end-point including age at radiotherapy (RT) (≤72 versus ≥73 years, median=72.5 years), gender, time from gastric cancer diagnosis to ECC (≤15 versus >15 months, median=15 months), metastatic spread to organs other than bone at RT (no versus yes), additional osseous lesions at RT (no versus yes), number of vertebral bodies afflicted by ECC (1 or 2 versus 3 or more), ambulatory function at RT (not able versus able to walk), dynamics of motor dysfunction (≤14 versus >14 days, median=14 days), performance status [more favorable: Eastern Cooperative Oncology Group (ECOG) score 1, 2 versus 3, 4], and type of RT (1×8 Gy/5×4 Gy versus 10×3 Gy/15×2.5 Gy/20×2 Gy).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Survival analyses (Kaplan-Meier method plus log-rank test).

The survival analyses were carried-out with the Kaplan–Meier method supplemented by the log-rank test. The factors that achieved a significant association with survival after Bonferroni adjustment for multiple tests (p<0.005 corresponds to an alpha-error of 5%) were incorporated in the scoring system.

Points for significant factors were derived by dividing the 3-month survival rates by 10. A patient's score was calculated by adding up their points for all factors.

Results

Four out of the 10 investigated factors had a significant influence on survival: metastatic spread to organs other than bone at RT (p<0.001), ambulatory function at RT (p=0.001), dynamics of motor dysfunction (p=0.002) and performance status (p=0.003). The complete survival analysis is shown in Table I. In order to avoid redundancy and confounding variables, the performance status was not incorporated into the scoring system. Performance status and ambulatory function are very similar. Patients who are able to walk generally have an ECOG score of 1 or 2 and those unable to walk an ECOG score of 3 or 4.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Scoring as obtained from the survival rates at 3 months.

The 3-month survival rates and the related points are summarized in Table II. The addition of the points resulted in possible total patient scores of 6, 12, 13, 19 or 26 points. The 3-month survival rates related to these points were 0%, 50%, 50%, 75% and 100%, respectively. Taking into account these 3-month rates, the patients were divided into four groups: 6 points, 12-13 points, 19 points and 26 points. The 3-month survival rates of these groups were 0%, 50%, 75% and 100%, respectively (p<0.001), and the 6-month rates were 0%, 0%, 25% and 100%, respectively (p<0.001).

Discussion

Outcomes of patients with metastatic gastric cancer are generally poor, despite the introduction of novel targeted therapies (5-8). Another option for improving the treatment results for these patients is personalization of the treatment approach. For appropriately tailoring of the treatment approach to patients with metastatic gastric cancer, it is mandatory to have an idea of the patient's expected survival duration. These times can be predicted with the aid of independent predictive factors and prognostic scoring systems that are available for several tumor types (9). In patients with gastric cancer, Ohi et al. identified tumor morphology and histopathology plus a pre-clinical marker and the lymphocyte count as clinical factors independently predictive of peritoneal metastasis (10). In another study of patients with gastric cancer, the nuclear expression of a chemokine receptor was associated with a worse prognosis (11).

In the current study, we aimed to identify predictors of survival in elderly patients with ECC from gastric cancer. According to the results, metastatic spread to organs other than bone at RT, ambulatory function at RT, dynamics of motor dysfunction and performance status showed a significant association with the patient's remaining life time. The negative outcomes in patients with widely spread metastatic disease and a poor performance status appear quite obvious. Furthermore, a poor performance status has a strong correlation with inability to walk, which explains the prognostic significance of the ambulatory function at RT. In the present study, the dynamics of motor dysfunction was also a significant predictor of survival. A faster development of dysfunction was associated with a worse survival. This can be explained by the fact that a faster development of motor weakness reflects a more aggressive tumor and more rapidly growing metastases, which likely translates into a worse survival prognosis (12, 13).

Three out of the four significant predictors were included in the scoring system. The performance status was not included to avoid redundant information and confounding variables due to the correlation with ambulatory function. Based on the 3-month rates, four groups were created: 6 points, 12-13 points, 19 points and 26 points. Out of the patients with 6 points, none survived for 3 months following RT. Therefore, these patients appear best treated with a single fraction of RT such as 1×8 Gy or 1×10 Gy, since these programs are similarly effective with respect to pain relief and functional outcomes compared to multifraction programs. In selected patients of the 6-points group, best supportive care alone may also be appropriate (14, 15). In the group with 12-13 points, half of the patients survived for 3 months but none for 6 months. Therefore, to avoid unnecessarily long overall treatment times, these patients should receive single-fraction RT or short-course multifraction RT such as 4×5 Gy in 4 days or 5×4 Gy and 5×5 Gy in a week. Out of the patients with 19 points, 75% survived for 3 months and 25% for 6 months. Since at 6 months following RT, local control of EEC becomes more important, these patients appear to be good candidates for 10×3 Gy in 2 weeks, which leads to less in-field recurrence of EEC (16, 17). Patients with 26 points had the most favorable survival; all patients of this group survived longer than 6 months. According to a matched-pair study of 382 patients with EEC from different primary tumor types and favorable survival prognoses, 15×2.5 Gy in 3 weeks and 20×2 Gy in 4 weeks were superior to 10x3 Gy with respect to local control of EEC, progression-free and overall survival (18). The 2-year rates were 92% versus 71% (p=0.012), 90% versus 68% (p=0.013) and 68% versus 53% (p=0.032), respectively. Therefore, patients with 26 points should be treated with 15×2.5 Gy or 20×2 Gy. Highly selected patients achieving 19 or 26 points may also be candidates for upfront decompressive surgery, which should be discussed with neurosurgeons or orthopedic surgeons prior to delivery of the first RT fraction (19).

In conclusion, in the present study, it was possible to identify four different survival groups of elderly patients with EEC from gastric cancer. The fractionation program of RT ranging from single-fraction RT to multi-fraction RT with overall treatment times of a few weeks must be adapted to the patient's remaining life span to ensure optimal personalization of this treatment.

Footnotes

  • Conflicts of Interest

    On behalf of all Authors, the corresponding Author states that there is no conflict of interest related to this study.

  • Received October 21, 2015.
  • Revision received November 23, 2015.
  • Accepted November 26, 2015.
  • Copyright © 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Rades D,
    2. Abrahm JL
    : The role of radiotherapy for metastatic epidural spinal cord compression. Nat Rev Clin Oncol 7: 590-598, 2010.
    OpenUrlCrossRefPubMed
  2. ↵
    Homepage of the World Health Organization (WHO). http://www.who.int/healthinfo/survey/ageingdefnolder/en.
  3. ↵
    1. Zhu W,
    2. Perez EA,
    3. Hong R,
    4. Li Q,
    5. Xu B
    : Age-related disparity in immediate prognosis of patients with triple-negative breast cancer: A population-based study from SEER cancer registries. PLoS One 10: e0128345, 2015.
    OpenUrlPubMed
  4. ↵
    1. Tian M,
    2. Zhu D,
    3. Chen D,
    4. Huo X,
    5. Ge J,
    6. Lu J,
    7. Zhang L,
    8. Shi J
    : Prognostic value of age in neurological cancer: an analysis of 22,393 cases from the SEER database. Tumour Biol, in press, 2015.
  5. ↵
    1. Kosaka T,
    2. Davydova J,
    3. Ono HA,
    4. Akiyama H,
    5. Hirai S,
    6. Ohno S,
    7. Takeshita F,
    8. Aoki K,
    9. Ochiya T,
    10. Yamamoto M,
    11. Kunisaki C,
    12. Endo I
    : Imaging and Antitumoral effect of a cyclo-oxygenase-2-specific replicative adenovirus for small metastatic gastric cancer lesions. Anticancer Res 35: 5201-5210, 2015.
    OpenUrlAbstract/FREE Full Text
    1. Kuo HY,
    2. Yeh KH
    : Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review. Anticancer Res 34: 3695-3699, 2014.
    OpenUrlAbstract/FREE Full Text
    1. Palacio S,
    2. Loaiza-Bonilla A,
    3. Kittaneh M,
    4. Kyriakopoulos C,
    5. Ochoa RE,
    6. Escobar M,
    7. Arango B,
    8. Restrepo MH,
    9. Merchan JR,
    10. Rocha Lima CM,
    11. Hosein PJ
    : Successful use of trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer. Anticancer Res 34: 301-306, 2014.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Sugimoto N,
    2. Fujitani K,
    3. Imamura H,
    4. Uedo N,
    5. Iijima S,
    6. Imano M,
    7. Shimokawa T,
    8. Kurokawa Y,
    9. Furukawa H,
    10. Goto M
    : Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402). Anticancer Res 34: 851-857, 2014.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Rades D,
    2. Dziggel L,
    3. Hakim SG,
    4. Rudat V,
    5. Janssen S,
    6. Trang NT,
    7. Khoa MT,
    8. Bartscht T
    : Predicting survival after irradiation for brain metastases from head and neck cancer. In Vivo 29: 525-528, 2015.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Ohi M,
    2. Mori K,
    3. Toiyama Y,
    4. Mohri Y,
    5. Okigami M,
    6. Yasuda H,
    7. Saigusa S,
    8. Tanaka K,
    9. Inoue Y,
    10. Kusunoki M
    : Preoperative prediction of peritoneal metastasis in gastric cancer as an indicator for neoadjuvant treatment. Anticancer Res 35: 3511-3518, 2015.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Masuda T,
    2. Nakashima Y,
    3. Ando K,
    4. Yoshinaga K,
    5. Saeki H,
    6. Oki E,
    7. Morita M,
    8. Oda Y,
    9. Maehara Y
    : Nuclear expression of chemokine receptor CXCR4 indicates poorer prognosis in gastric cancer. Anticancer Res 34: 6397-6403, 2014.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Rades D,
    2. Dunst J,
    3. Schild SE
    : The first score predicting overall survival in patients with metastatic spinal cord compression. Cancer 112: 157-161, 2008.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Rades D,
    2. Douglas S,
    3. Veninga T,
    4. Stalpers LJA,
    5. Hoskin PJ,
    6. Bajrovic A,
    7. Adamietz IA,
    8. Basic H,
    9. Dunst J,
    10. Schild SE
    : Validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression. Cancer 116: 3670-3673, 2010.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Rades D,
    2. Stalpers LJ,
    3. Veninga T,
    4. Schulte R,
    5. Hoskin PJ,
    6. Obralic N,
    7. Bajrovic A,
    8. Rudat V,
    9. Schwarz R,
    10. Hulshof MC,
    11. Poortmans P,
    12. Schild SE
    : Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression in a series of 1304 patients. J Clin Oncol 23: 3366-3375, 2005.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Rades D,
    2. Hueppe M,
    3. Schild SE
    : A score to identify patients with metastatic spinal cord compression who may be candidates for best supportive care. Cancer 119: 897-903, 2013.
    OpenUrlPubMed
  14. ↵
    1. Rades D,
    2. Fehlauer F,
    3. Schulte R,
    4. Veninga T,
    5. Stalpers LJ,
    6. Basic H,
    7. Bajrovic A,
    8. Hoskin PJ,
    9. Tribius S,
    10. Wildfang I,
    11. Rudat V,
    12. Engenhart-Cabilic R,
    13. Karstens JH,
    14. Alberti W,
    15. Dunst J,
    16. Schild SE
    : Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol 24: 3388-3393, 2006.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Rades D,
    2. Lange M,
    3. Veninga T,
    4. Stalpers LJ,
    5. Bajrovic A,
    6. Adamietz IA,
    7. Rudat V,
    8. Schild SE
    : Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 79: 524-530, 2011.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Rades D,
    2. Panzner A,
    3. Rudat V,
    4. Karstens JH,
    5. Schild SE
    : Dose escalation of radiotherapy for metastatic spinal cord compression (MSCC) in patients with relatively favorable survival prognosis. Strahlenther Onkol 187: 729-735, 2011.
    OpenUrlPubMed
  17. ↵
    1. Patchell R,
    2. Tibbs PA,
    3. Regine WF,
    4. Payne R,
    5. Saris S,
    6. Kryscio RJ,
    7. Mohiuddin M,
    8. Young B
    : Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366: 643-648, 2005.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

In Vivo: 30 (1)
In Vivo
Vol. 30, Issue 1
January-February 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Personalized Radiotherapeutic Approaches for Elderly Patients with Epidural Cord Compression from Gastric Cancer
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Personalized Radiotherapeutic Approaches for Elderly Patients with Epidural Cord Compression from Gastric Cancer
DIRK RADES, STEVEN E. SCHILD, AMIRA BAJROVIC, STEFAN JANSSEN, TOBIAS BARTSCHT
In Vivo Jan 2016, 30 (1) 69-72;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Personalized Radiotherapeutic Approaches for Elderly Patients with Epidural Cord Compression from Gastric Cancer
DIRK RADES, STEVEN E. SCHILD, AMIRA BAJROVIC, STEFAN JANSSEN, TOBIAS BARTSCHT
In Vivo Jan 2016, 30 (1) 69-72;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • How Should Palliative Thoracic Radiotherapy Be Fractionated for Octogenarians with Lung Cancer?
  • Predictive Factors and a Survival Score for Patients Irradiated for Metastatic Spinal Cord Compression from Carcinoma of the Salivary Glands
  • A New Prognostic Instrument Specifically Designed for Patients Irradiated for Recurrent Carcinoma of the Bladder
  • Google Scholar

More in this TOC Section

  • Slowly Progressive Bone Marrow Metastasis of Gastric Cancer Followed-up Without Treatment
  • Evaluation of the Time to Onset and Outcome of Lenalidomide-induced Thrombosis and Embolism Using Spontaneous Reporting Database
  • Efficacy of Ascorbic Acid, Thiamine, and Hydrocortisone Combination Therapy: Meta-analysis of Randomized Controlled Trials
Show more Clinical Studies

Similar Articles

Keywords

  • Gastric cancer
  • epidural cord compression
  • elderly patients
  • personalization of treatment
In Vivo

© 2023 In Vivo

Powered by HighWire